NSG BioLabs Enter into Collaborates with Merck to Boost Biotech Start-ups and Drive Innovation
Friday, August 16, 2024
NSG BioLabs has partnered with Merck to boost the research and development capabilities of NSG BioLabs' tenants.
This collaboration aims to offer biotech start-ups access to vital resources and expertise, facilitating opportunities for funding, partnerships, production, and commercialization.
NSG BioLabs is to cultivate an environment where our residents can thrive. This partnership will provide them with exclusive access to Merck’s scientists, engineers, cutting-edge equipment, consumables, and services, allowing them to push forward with their research and innovations. Together shaping the future of life sciences and driving significant discoveries.
Partnership with NSG BioLabs highlights Merck’s commitment to nurturing the biotech community in Singapore and across the Asia Pacific region. Merck offers one of the industry’s most extensive portfolios for research discovery, pharmaceutical development, testing, and manufacturing. Additionally, M Lab™ Collaboration Centre in Singapore provides off-site trial support and training in a GMP-like environment.
Since 2019, NSG BioLabs has been a key player in supporting innovators across sectors such as health, biomedical, agrifood, and industrial biotechnology. The company focuses on areas like precision medicine, nucleic acids, AI-driven drug discovery, and synthetic biology.
With the largest co-working biotech laboratory and office space in Singapore and extensive networks with local and international partners, NSG BioLabs has supported over 40 resident companies. These include multi-billion-dollar multinationals and promising start-ups that have collectively raised nearly US$400 million and created hundreds of jobs.
NSG BioLabs has been providing biotech start-ups and multinational companies with BSL-2 certified private and shared laboratories, offices, equipment, and privileged access to service providers and suppliers. Since opening its first site in November 2019, NSG BioLabs has expanded with a second site in August 2021 and a third in 2023, now totalling 35,000 square feet in Singapore’s R&D ecosystem. As one of the region’s largest private biotech incubators, and with strong partnerships and strategic investors like Celadon Partners and ClavystBio (a life sciences investor established by Temasek), NSG BioLabs is well-positioned to continue enhancing its infrastructure, services, and networks for its growing community.
Source:prnasia.com
